Alzheimer's Disease International (ADI)
News, blogs and stories from across the field of dementia, the work of Alzheimer’s Disease International and our members.
The month of March has marked significant progress in the development and implementation of National Dementia Plans (NDPs), with the #WhatsYourPlan campaign leading to the launch of plans in Uruguay and Armenia, bringing the total number of WHO Member States with NDPs to 41.
Silverado Senior Living is the first care home provider to receive ADI Accreditation since the launch of the accreditation programme in 2021.
Alzheimer and dementia associations in the Caribbean are calling for National Dementia Plans to be created and implemented through the #WhatsYourPlan campaign.
Following the launch of the #WhatsYourPlan campaign in November 2021, ADI examines the campaign’s successes in its first year.
Lecanemab is the second Alzheimer’s disease pharmaceutical treatment to come to market since 2003, following the conditional approval of Aduhlem (aducanumab) in June 2022.
In this blog, members of the ADI team look back at 2022 and write about their hopes and aspirations for 2023.
In this blog, the authors of 'Occupational Therapy and Dementia' discuss the importance of occupational therapy in better supporting people living with dementia, as well as raising awareness about reducing the risk of dementia.
Most people associate dementia with older adults; however, dementia can impact all age groups, including children.
A joint letter was submitted in anticipation of the 3rd session of the World Health Organization's Intergovernmental Negotiating Body on 5-7 December.
Eisai presented the results of their confirmatory Phase 3 clinical trial (CLARITY AD) at the 15th Clinical Trials on Alzheimer’s Disease (CTAD) conference in San Francisco, which many are hailing as positive news for the field.